Pulmonary function is an easily measurable and reliable index of the physiological state of the lungs and airways 1 . Pulmonary function also predicts mortality in the general population, even among people who have never smoked (never-smokers) who have only modestly reduced pulmonary function and no respiratory symptoms 2,3 . The peak level of pulmonary function attained in early adulthood and its subsequent decline with age are likely influenced by genetic and environmental factors. Tobacco smoking is a major environmental cause of accelerated decline in pulmonary function with age. Other inhaled pollutants also appear to contribute. Familial aggregation studies suggest a genetic contribution to lung function, with heritability estimates exceeding 40% 4,5 , but little is known about the specific genetic factors involved. A relatively uncommon deficiency of α1-antitrypsin is the only established genetic risk factor for accelerated decline in pulmonary function and for development of chronic obstructive pulmonary disease (COPD), especially in smokers 4, 6 . However, α1-antitrypsin accounts for little of the population variability in pulmonary function 4 . Candidate gene studies suggest that other genetic variants may influence the time course of pulmonary function and its decline in relation to smoking, but these putative genetic risk factors remain unknown 4 .
Pulmonary function is an easily measurable and reliable index of the physiological state of the lungs and airways 1 . Pulmonary function also predicts mortality in the general population, even among people who have never smoked (never-smokers) who have only modestly reduced pulmonary function and no respiratory symptoms 2, 3 . The peak level of pulmonary function attained in early adulthood and its subsequent decline with age are likely influenced by genetic and environmental factors. Tobacco smoking is a major environmental cause of accelerated decline in pulmonary function with age. Other inhaled pollutants also appear to contribute. Familial aggregation studies suggest a genetic contribution to lung function, with heritability estimates exceeding 40% 4, 5 , but little is known about the specific genetic factors involved. A relatively uncommon deficiency of α1-antitrypsin is the only established genetic risk factor for accelerated decline in pulmonary function and for development of chronic obstructive pulmonary disease (COPD), especially in smokers 4, 6 . However, α1-antitrypsin accounts for little of the population variability in pulmonary function 4 . Candidate gene studies suggest that other genetic variants may influence the time course of pulmonary function and its decline in relation to smoking, but these putative genetic risk factors remain unknown 4 .
Forced expiratory volume in the first second (FEV 1 ) and its ratio to forced vital capacity (FEV 1 /FVC) are two clinically relevant pulmonary function measures. Although both FEV 1 and FVC are influenced by lung size and can be reduced by restrictive lung diseases, obstructive lung disease leads to proportionately greater reduction in FEV 1 than FVC. Therefore, reduced FEV 1 /FVC, an indicator of airflow obstruction that is independent of lung size, is the primary criterion for defining an obstructive ventilatory defect 1 . Whereas low FEV 1 /FVC indicates the presence of airflow obstruction, FEV 1 is used to classify the severity and follow the progression of obstructive lung disease over time 5, 7, 8 .
The first genome-wide association study (GWAS) for pulmonary function evaluating 70,987 SNPs in about 1,220 Framingham Heart Study (FHS) participants revealed no genome-wide significant loci 9 . Recently, a GWAS of FEV 1 /FVC using 2,540,223 SNPs in 7,691 FHS participants identified several SNPs on chromosome 4q31 near HHIP with genome-wide significance 10 . A GWAS of COPD 11 also implicated the HHIP region along with CHRNA3-CHRNA5 on chromosome 15, a region previously associated with nicotine dependence 12, 13 .
We conducted meta-analyses of GWAS results for a cross-sectional analysis of pulmonary function (FEV 1 /FVC and FEV 1 ) in 20,890 individuals of European ancestry from four Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium 14 studies: Atherosclerosis Risk in Communities (ARIC), Cardiovascular Health Study (CHS), FHS and Rotterdam Study (RS-I and RS-II). Given that cigarette smoking is a major risk factor for pulmonary function decline, we conducted meta-analyses with adjustment for smoking status and quantity (pack-years), and in subgroups of those who have ever smoked (ever-smokers) and never-smokers. Loci meeting genomewide significance and other selected high-signal hits were evaluated for replication with the SpiroMeta consortium, an independent consortium Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function of PID1 (Fig. 2g) were also significantly associated with FEV 1 /FVC in all participants. SNPs in AGER, PPT2, PTCH1 and PID1 had minor allele frequencies (MAFs) between 4% and 10%, whereas all other significantly associated SNPs had MAFs exceeding 10%. Absolute values of β (per-allele change) for FEV 1 /FVC ranged from 0.44% to 1.14%. The directions of β were consistent across the CHARGE cohorts for all genome-wide significant SNPs except for the GPR126 SNPs noted in Supplementary Table 2 . A borderline significant association (P = 5.37 × 10 -8 , MAF = 0.42, β = -0.43) with FEV 1 /FVC was noted for the chromosome 5q33.1 SNP rs11168048 in HTR4 (Fig. 2h) . 
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Cohort-specific association results for SNPs with the smallest P value from each locus implicated at or near genome-wide significance are shown in Supplementary Table 3 .
For FEV 1 , genome-wide significant associations were observed for 46 SNPs on chromosome 4q24 in or near four adjacent genes (Supplementary Table 4 ). The SNP with the smallest P value, rs17331332 (P = 4.00 × 10 -10 ), is located near NPNT. The 45 other significantly associated SNPs include four SNPs located near the 5′ end of NPNT, 5 SNPs located in INTS12 or near its 3′ end, seven SNPs located in FLJ20184 or near its 3′ end and 29 SNPs located in GSTCD. FLJ20184 encodes a hypothetical protein, according to several genome browsers including the UCSC Genome Browser (see URLs) 16 , but there is no approved Human Gene Organization (HUGO) gene name for this locus 17 . The SNP rs17331332 is correlated at r 2 > 0.5 with most other significantly associated SNPs in this region (Fig. 3) , suggesting that the associations in the four adjacent genes represent one independent finding. The significantly associated SNPs had MAFs between 6% and 8%. The absolute β (per-allele change) values for FEV 1 ranged from 55.92 to 71.43 ml (Supplementary  Table 4) , and the β directions were consistent across the CHARGE cohorts for all 46 genome-wide significant SNPs (Supplementary Table 3 for rs17331332). Among these 46 SNPs, 39 were associated with FEV 1 at genome-wide significance among ever-smokers (Supplementary Table 4) .
To evaluate whether other loci may also influence pulmonary function, we created Q-Q plots for FEV 1 /FVC and FEV 1 among all participants after removing SNPs at or close to genome-wide significance and nearby SNPs correlated at r 2 > 0.2 with the top SNP for each locus (totaling 1,862 SNPs removed for FEV 1 /FVC and 284 SNPs removed for FEV 1 ). The resulting Q-Q plots show some excess of small P values for FEV 1 /FVC ( Supplementary  Fig. 4a ) and FEV 1 (Supplementary Fig. 4b ) over expectation.
Putative functional polymorphisms
Three SNPs among the 119 genome-wide significant SNPs for FEV 1 / FVC are nonsynonymous (missense) polymorphisms: rs11155242 
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(resulting in a lysine-to-glutamine substitution) in GPR126, rs1422795 (serine-to-glycine substitution) in ADAM19 and rs2070600 (glycineto-serine substitution) in AGER. The Polymorphism Phenotyping (PolyPhen) program (see URLs) 18 predicts that the amino acid substitutions resulting from rs11155242 and rs1422795 cause benign changes but that rs2070600 has a possibly damaging impact on the structure and function of AGER. All other SNPs implicated for FEV 1 /FVC or FEV 1 are intergenic, intronic or located in 3′ untranslated regions. Of these, three intronic GPR126 SNPs (rs9496346, rs1040525 and rs6929442) and one intergenic SNP near NPNT (rs10516529) are located in transcription factor binding sites, according to the UCSC Genome Browser (see URLs) 16 .
Replication with the SpiroMeta consortium
Thirty high-signal SNPs associated with FEV 1 /FVC (18 SNPs from eight loci) or FEV 1 (12 SNPs from three loci) at or close to genomewide significance were tested for replication in the SpiroMeta consortium, with results reported in a companion paper 15 . We evaluated these SNPs in 16,178 SpiroMeta participants of European ancestry with complete quantitative smoking data using the CHARGE analytic method (see statistical analysis section of Online Methods), which included adjustment for smoking status and pack-years, and performed joint meta-analyses of CHARGE GWAS and SpiroMeta replication results (Tables 2 and 3) . P values that exceeded the significance threshold in SpiroMeta (P < 8.33 × 10 -4 based on 60 tests) or the genome-wide significance threshold in joint meta-analyses (P < 5 × 10 -8 ) were considered significant evidence for replication at their corresponding SNPs. For FEV 1 /FVC, among 18 SNPs tested for replication, six SNPs in three loci were significantly associated with this measure in SpiroMeta: rs1980057 and rs1032295 near HHIP (r 2 = 0.72), rs2070600 in AGER and rs10947233 in PPT2 (r 2 = 0.66), and rs11168048 and rs7735184 in HTR4 (r 2 = 0.93) ( Table 2) . Their joint meta-analysis P values ranged from 3.21 × 10 -20 to 6.23 ×10 -11 ( Table 2) . Five additional SNPs in GPR126 (rs3817928, rs7776375 and rs6937121) and ADAM19 (rs2277027 and rs1422795) were not significantly associated with FEV 1 /FVC at genome-wide significance in SpiroMeta alone, but these SNPs were associated at genome-wide significance in the joint metaanalysis, with P values ranging from 9.93 × 10 -11 to 1.25 × 10 -8 ( Table 2) . For replicated SNPs, the allele frequencies and the direction and magnitude of the associations with FEV 1 /FVC were similar between consortia ( Table 2) . Further, the HHIP, ADAM19 and HTR4 SNPs were significantly associated with FEV 1 in SpiroMeta (Supplementary Table 5 ). The HHIP SNP rs1980057 and the HTR4 SNPs rs11168048 and rs7735184 were also associated with FEV 1 at genome-wide significance in the joint meta-analysis (P ranging from 5.86 × 10 -9 to 1.58 × 10 -8 , Supplementary Table 5) . SNPs in FAM13A, PTCH1 and PID1 that gave genome-wide significance in CHARGE were not confirmed in analyses with SpiroMeta.
For FEV 1 , among the 12 SNPs tested for replication, eight SNPs from one locus with four adjacent genes were significantly associated with this measure in SpiroMeta, including rs17331332 and rs17036341 near NPNT, rs11727189 and rs17036090 in or near INTS12, rs17036052 and rs17035960 in or near FLJ20184, and rs11097901 and rs11728716 in GSTCD ( Table 3) . For replicated SNPs, the allele frequencies and the direction and magnitude of the associations with FEV 1 were similar between consortia, and P values from joint meta-analysis ranged from 4.66 × 10 -17 to 9.42 × 10 -14 ( Table 2) . None of these SNPs were significantly associated with FEV 1 /FVC in CHARGE or SpiroMeta (Supplementary Table 5 ).
Associations in individuals with normal pulmonary function
To address whether the genetic associations hold even among people with normal pulmonary function, we repeated the meta-analyses after excluding individuals with asthma or COPD, leaving 17,855 individuals (n = 6,912 from ARIC, n = 2,634 from CHS, n = 6,371 from FHS, n = 1,126 from RS-I and n = 812 from RS-II). Asthma was defined by self-report of ever having asthma or self-report of ever having physician-diagnosed asthma. COPD was defined spirometrically as having both FEV 1 /FVC and FEV 1 less than the lower limit of normal values using National Health and Nutrition Examination Survey III prediction equations 19, 20 . Comparing the original meta-analyses to the meta-analyses with exclusions for asthma and COPD, β estimates were highly correlated for the high-signal SNPs tested for replication (Pearson's r > 0.99 for 18 FEV 1 /FVC SNPs and 12 FEV 1 SNPs). β estimates remained highly correlated for SNPs with P values as high as 0.01 in the original meta-analyses (r = 0.92 for FEV 1 /FVC and r = 0.96 for FEV 1 ). As expected, there was some attenuation in P values for many of the SNPs in our implicated loci given the substantial power loss due to both reduced sample size and the truncation of the FEV 1 /FVC and FEV 1 distributions, but there was substantial overlap in the top-ranking SNPs between the two meta-analyses (data not shown). The P values for some topranking SNPs became smaller, including several ADAM19, FAM13A and HTR4 SNPs associated with FEV 1 /FVC. Of note, 12 SNPs in HTR4, a locus with one SNP, rs11168048, showing borderline genome-wide significance in the original meta-analysis showed genome-wide significance in the subset of individuals without asthma or COPD (P = 6.93 × 10 -9 for rs11168048).
DISCUSSION
In meta-analyses of GWAS results in 20,890 CHARGE participants of European ancestry, we identified genome-wide significant associations with FEV 1 /FVC for SNPs in seven previously unrecognized independent loci (GPR126, ADAM19, AGER-PPT2, FAM13A, PTCH1, PID1 and HTR4) and with FEV 1 for one previously unrecognized independent locus annotated by at least three genes (INTS12-GSTCD-NPNT). The SpiroMeta consortium independently reported genome-wide significant associations of GSTCD, HTR4, AGER, TNS1 and THSD4 with FEV 1 /FVC and FEV 1 (companion paper in this issue, ref. 15 ). Both consortia confirm previous GWAS findings implicating the HHIP region for FEV 1 /FVC 10 .
Several SNPs near the gene encoding the hedgehog interacting protein (HHIP) were associated with FEV 1 /FVC at genome-wide significance in CHARGE and SpiroMeta, confirming earlier GWAS findings in FHS 10 . The hedgehog (Hh) signaling pathway is crucial in several embryonic development processes, including the branching morphogenesis of the lung 21, 22 . Furthermore, several polymorphisms in three genes in the Hh signaling pathway (IHH, HHIP and PTCH1) were significantly associated with adult height in a previous GWAS 23 . Several PTCH1 SNPs were also significantly associated with FEV 1 /FVC in CHARGE, but these associations were not confirmed in SpiroMeta 15 . Epithelial cells produce Hh protein, which binds to its membrane receptor (encoded by PTCH1) on mesenchymal cells and orchestrates tissue and organ patterning. Hh pathway dysfunction during the fetal stage in humans is responsible for severe lung malformations 24, 25 . In adults, the Hh-signaling pathway may participate in the response of the airway epithelium to injury, such as smoking and hyperoxia 26, 27 .
A nonsynonymous AGER SNP (rs2070600) was associated with FEV 1 /FVC at genome-wide significance in our study and independently confirmed in SpiroMeta 15 . The AGER protein, a membranebound or soluble pattern-recognition receptor, belongs to the immunoglobulin superfamily of cell surface receptors. The SNP rs2070600 has functional significance: for example, it promotes higher ligand affinity and the production of proinflammatory proteins upon activation 28 . In healthy adult mice and humans, AGER is highly expressed in the lungs 29 , and its absence contributes to the pathogenesis of idiopathic pulmonary fibrosis 30, 31 . AGER signaling is involved in host defense, inflammation and tissue remodeling, processes that are relevant to accelerated decline in pulmonary function with age.
Polymorphisms in HTR4 were associated with FEV 1 /FVC at genome-wide significance in the joint meta-analysis of CHARGE and SpiroMeta results. HTR4 encodes a G-coupled transmembrane receptor that regulates cyclic AMP production in response to 5-hydroxytryptamine (serotonin). Elevated levels of free serotonin have been found in the plasma of individuals with symptomatic asthma 32 , and serotonin signaling pathways involving HTR4 have been implicated in cholinergic and immune-mediated airway reactivity 33, 34 . Upon activation by serotonin, HTR4 in human airway epithelial cells regulates the release of a proinflammatory cytokine, a signature characteristic of asthma 35 .
ADAM19 SNPs were associated with FEV 1 /FVC at genomewide significance in CHARGE and in the joint meta-analysis with SpiroMeta. ADAM19 is a member of 'a disintegrin and metalloprotease' (ADAM) family of membrane-anchored glycoproteins that control cell-matrix interactions and help regulate growth and A r t i c l e s morphogenesis. Polymorphisms in a gene that encodes for another ADAM family member, ADAM33, have been associated with bronchial hyper-responsiveness and accelerated lung function decline in those with asthma and in the general population [36] [37] [38] . ADAM19 has not been previously implicated in human pulmonary disorders, but it is abundantly expressed in alveolar epithelial cells and bronchial smooth muscle tissue 39 .
GPR126 polymorphisms were associated with FEV 1 /FVC at genomewide significance in CHARGE and in the joint meta-analysis with SpiroMeta. GPR126 belongs to a superfamily of G protein-coupled receptors involved in cell adhesion and signaling 40 . Although the precise function of this gene has not been elucidated, its expression in mice is temporally increased during embryonic organ development and is highest in the adult lungs 41 . In humans, recent GWAS have linked GPR126 variants with adult height, and more specifically with trunk height [42] [43] [44] . We adjusted all analyses for standing height. Therefore, we repeated analyses after adjusting for sitting height (a more reliable indicator of trunk height) for GPR126 SNPs in ARIC, where both height variables were measured, and associations with FEV 1 /FVC remained significant (data not shown). Thus, these associations are not likely to be due to residual confounding by trunk height.
Genome-wide significant associations with FEV 1 were observed in CHARGE for numerous SNPs spanning at least three genes on chromosome 4q24, and these associations were significant for all eight SNPs tested for replication in SpiroMeta ( Table 3) . There is moderate to strong linkage disequilibrium among the chromosome 4q24 SNPs, and the specific genes influencing FEV 1 remain speculative. The genes are ordered INTS12-GSTCD-NPNT along chromosome 4q24, and joint meta-analysis with SpiroMeta showed that SNPs from the genes INTS12 and GSTCD had the most significant associations with FEV 1 ( Table 3 ). The product of INTS12 is a subunit of the integrator complex that associates with the C-terminal domain of RNA polymerase II and mediates 3′-end processing of small nuclear RNAs 45 . The glutathione S-transferase C-terminal domain (GSTCD) could influence lung function via mechanisms involving the detoxification by glutathione S-transferases of xenobiotics that might damage the lungs.
The most distal gene in the chromosome 4q24 region, NPNT, encodes nephronectin, which is expressed in fetal and adult lungs 46, 47 . The NPNT SNP rs10516529 is located in a binding site for the transcription factor POU6F1 (also known as mPOU homeobox protein), which is known to be expressed in adult lungs and hypothesized to play a role in lung development [48] [49] [50] . A fourth predicted gene in the region, FLJ20184, is located proximal to the other three genes. Although FLJ20184 encodes a hypothetical protein of unknown function, FLJ20184 contains allelic variants associated with successful smoking cessation in a GWAS of patients in smoking cessation trials 51 .
The genetic factors identified here gave estimated effect sizes consistent with those for well-established risk factors for pulmonary function decline. Carrying one copy of an implicated reference allele resulted in a FEV 1 difference ranging from 50-70 mL. These effect sizes correspond to approximately 2.8-3.9 years of age-related decline in pulmonary function based on a mean decline of about 18 mL/year and to approximately 1.7-2.3 years of active smoking-related decline based on a mean decline of about 30 mL/year 52 . Second-hand smoke exposure has also been associated with decline in FEV 1 (15 mL decline for a 10-year exposure in the home and 41 mL decline for a 10-year workplace exposure) 53 . For FEV 1 /FVC, carrying one copy of an implicated reference allele resulted in a difference ranging from 0.30% to 1%. The lower effect-size estimates are comparable with the mean FEV 1 /FVC decline related to second-hand smoking (0.35 for a 10-year exposure in the home and 0.14 for a 10-year workplace exposure) 53 .
These comparisons demonstrate that the identified genetic factors have a moderate impact on pulmonary function. Individuals carrying these polymorphisms will have lower pulmonary function than predicted at a given age, thus placing them at greater risk for developing COPD and at a greater risk of mortality 2, 3 .
A GWAS of COPD identified CHRNA3-CHRNA5 on chromosome 15 as a susceptibility locus 11 . CHRNA3-CHRNA5 has also been associated with nicotine dependence 12, 13 . In CHARGE, one identified SNP in this locus (rs1051730) was associated with FEV 1 /FVC (P = 0.00070) and FEV 1 (P = 0.016), whereas the other identified SNP in this locus (rs8034191) was not associated with FEV 1 /FVC (P = 0.11) or FEV 1 (P = 0.36). The nominal evidence for replication may reflect differences in study design and a potential gene-environment interaction involving smoking.
Our study has several important strengths. The CHARGE cohorts are well phenotyped with pulmonary function measures passing stringent quality control criteria, thus minimizing measurement error. Our large sample size of 20,890 participants offers a powerful resource to examine associations of common SNPs with modest to large effects 14 . Testing our most significant results in the SpiroMeta consortium provided independent replication of these associations. However, even with the large sample sizes in these combined consortia, we likely have insufficient power to detect associations of polymorphisms with small effect sizes or low frequencies.
Population-based cohorts are subject to population stratification, and analytic steps were taken to minimize this potential bias. Cohortspecific λ gc values were low (1.00-1.05), and a genomic control adjustment was made in the meta-analyses to reduce inflation in the test statistics. The two largest cohorts, with the largest (albeit modest) λ gc values (ARIC and FHS), incorporated principal components as potential confounders in their cohort-specific association tests. Although we cannot eliminate the possibility that some findings are subject to residual confounding by population stratification, the Q-Q plots showing deviations between observed and expected P values for many high-to moderate-signal SNPs and the replication of association for multiple top loci in SpiroMeta suggest a multifactorial influence on pulmonary function.
Our study identified several previously unrecognized loci related to two clinically important pulmonary function measures with evidence for replication, including GPR126, ADAM19, AGER-PPT2 and HTR4 for FEV 1 /FVC and INTS12-GSTCD-NPNT for FEV 1 and confirmed previous reports of association with FEV 1 /FVC in the HHIP region. These loci include genes with biologically plausible functions, and their identification here encourages future investigations to examine the mechanisms underlying their influence on pulmonary function. Fine mapping of these regions is needed to identify and characterize functional variants. Understanding the genetic determinants of pulmonary function is paramount in identifying the biological mechanisms that lead to its decline and in ultimately lessening the mortality burden associated with reduced pulmonary function.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website. the SpiroMeta GWAS. We aimed to select two SNPs from each of the top genes implicated for FEV 1 /FVC or FEV 1 , with nearly all the genes exceeding genome-wide significance. The SNP with the lowest P value in or near each gene was selected. A second SNP, genotyped (instead of imputed) in at least one cohort, was selected with preference for nonsynonymous SNPs and SNPs not in strong linkage disequilibrium with the first selected SNP. Only one SNP was available for AGER, PPT2, TSPYL4 and NT5DC1. Four SNPs were selected from two linkage disequilibrium blocks for the largest gene, GPR126. In total, 18 SNPs from 9 genes (8 independent loci) implicated for FEV 1 /FVC and 12 SNPs from 7 genes (3 independent loci) implicated for FEV 1 were tested for replication.
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